Pigment Cell & Melanoma Research最新文献_第10页

Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era 免疫疗法时代晚期黑色素瘤患者临终时的死亡原因和转移性疾病模式。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-28 DOI: 10.1111/pcmr.13188

Daniel Y. Lee, Madeline McNamara, Alexander Yang, Maxim Yaskolko, Harriet Kluger, Thuy Tran, Kelly Olino, James Clune, Mario Sznol, Jeffrey J. Ishizuka

{"title":"Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era","authors":"Daniel Y. Lee, Madeline McNamara, Alexander Yang, Maxim Yaskolko, Harriet Kluger, Thuy Tran, Kelly Olino, James Clune, Mario Sznol, Jeffrey J. Ishizuka","doi":"10.1111/pcmr.13188","DOIUrl":"10.1111/pcmr.13188","url":null,"abstract":"Despite remarkable advances in immunotherapy, melanoma remains a significant cause of cancer mortality. Many factors concerning melanoma mortality are poorly understood, posing an obstacle to optimal care. We conducted a retrospective observational cohort study of 183 patients with metastatic melanoma who died following immunotherapy treatment to investigate sites of metastases at death, settings of death, and mechanisms of death. The median time from metastatic diagnosis to death was 16.1 months (range 0.3–135.1 months). Most patients experienced hospitalization within 3 months before death (80.3%), with 31.7% dying while hospitalized, 31.2% while in inpatient hospice, and 29.4% while in home hospice. The most common sites of metastases at death were distant lymph nodes (62.8%), lung (57.9%), liver (50.8%), brain (38.8%), and bone (37.7%). The most common causes of death were progressive failure to thrive (57.5%), respiratory failure (22.4%), and infection (21.8%); the vast majority (87.9%) of patients died from melanoma-specific causes. Overall, 10.9% of patients in our cohort had survival >5 years after metastatic diagnosis, and 76.2% of long-term survivors died due to melanoma. This study describes factors associated with melanoma mortality, highlighting an ongoing need for therapeutic advancements.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"847-853"},"PeriodicalIF":3.9,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141786666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conventional suspension delivery versus tattooing pen-assisted suspension delivery in non-cultured epidermal cell suspension procedure for vitiligo: A randomized controlled trial 在治疗白癜风的非培养表皮细胞悬浮术中，传统悬浮给药法与纹身笔辅助悬浮给药法的比较：随机对照试验。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-19 DOI: 10.1111/pcmr.13187

Akshay Meena, Keshavamurthy Vinay, Muthu Sendhil Kumaran, Sheetanshu Kumar, Anuradha Bishnoi, Davinder Parsad

{"title":"Conventional suspension delivery versus tattooing pen-assisted suspension delivery in non-cultured epidermal cell suspension procedure for vitiligo: A randomized controlled trial","authors":"Akshay Meena, Keshavamurthy Vinay, Muthu Sendhil Kumaran, Sheetanshu Kumar, Anuradha Bishnoi, Davinder Parsad","doi":"10.1111/pcmr.13187","DOIUrl":"10.1111/pcmr.13187","url":null,"abstract":"Non-cultured epidermal suspension (NCES) is one of the most widely used surgical therapy for stable vitiligo patients in which recipient size preparation plays an important role in the outcome of NCES. The primary objective is to evaluate and compare the efficacy and safety of conventional suspension delivery after manual dermabrasion (CSMD) versus tattooing pen-assisted suspension delivery (TPSD) in NCES. Paired vitiligo units (VU) in 36 patients, matched with respect to size and location were divided into two groups. The VU in Group 1 underwent suspension delivery by CSMD while the VU in Group 2 underwent same by TPSD. All the VU were followed up at regular intervals until 24 weeks. At the end of 24 weeks, 31 VU (86.1%) in Group 1 achieved >75% repigmentation which was significantly higher (p = .02, chi-square test) as compared to 22 VU (61.1%) in Group 2. The color matching in both the groups VU was also comparable (p = .84, chi-square test). The patient global assessment (PGA) was significantly higher in Group 1 VU as compared to Group 2. Treatment response in terms of repigmentation and PGA was significantly better in VU treated with CSMD as compared to TPSD. Recipient site complications were seen more commonly in Group 1 VU as compared to Group 2. Perilesional halo at the recipient site was seen in none of the VU in Group 2 which was significantly lower than 6 VU in Group 1 than (p = .02, chi-square test). Better results may be possible with technical improvisations in tattooing pen needle diameter and depth of penetration.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"839-846"},"PeriodicalIF":3.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma 葡萄膜黑色素瘤肝转移患者临床和放射学参数的预后价值。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-12 DOI: 10.1111/pcmr.13184

Mael Lever, Simon Bogner, Melina Giousmas, Fabian D. Mairinger, Hideo A. Baba, Heike Richly, Tanja Gromke, Martin Schuler, Nikolaos E. Bechrakis, Halime Kalkavan

{"title":"Prognostic value of clinical and radiomic parameters in patients with liver metastases from uveal melanoma","authors":"Mael Lever, Simon Bogner, Melina Giousmas, Fabian D. Mairinger, Hideo A. Baba, Heike Richly, Tanja Gromke, Martin Schuler, Nikolaos E. Bechrakis, Halime Kalkavan","doi":"10.1111/pcmr.13184","DOIUrl":"10.1111/pcmr.13184","url":null,"abstract":"Approximately every second patient with uveal melanoma develops distant metastases, with the liver as the predominant target organ. While the median survival after diagnosis of distant metastases is limited to a year, yet-to-be-defined subgroups of patients experience a more favorable outcome. Therefore, prognostic biomarkers could help identify distinct risk groups to guide patient counseling, therapeutic decision-making, and stratification of study populations. To this end, we retrospectively analyzed a cohort of 101 patients with newly diagnosed hepatic metastases from uveal melanoma by using Cox-Lasso regression machine learning, adapted to a high-dimensional input parameter space. We show that substantial binary risk stratification can be performed, based on (i) clinical and laboratory parameters, (ii) measures of quantitative overall hepatic tumor burden, and (iii) radiomic parameters. Yet, combining two or all three domains failed to improve prognostic separation of patients. Additionally, we identified highly relevant clinical parameters (including lactate dehydrogenase, thrombocyte counts, aspartate transaminase, and the metastasis-free interval) at first diagnosis of metastatic disease as predictors for time-to-treatment failure and overall survival. Taken together, the risk stratification models, built by our machine-learning algorithm, identified a comparable and independent prognostic value of clinical, radiological, and radiomic parameters in uveal melanoma patients with hepatic metastases.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"831-838"},"PeriodicalIF":3.9,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series 检测脑脊液中的游离细胞肿瘤 DNA 作为脑膜黑色素瘤转移的诊断生物标志物：病例系列。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-11 DOI: 10.1111/pcmr.13186

Iris Dirven, Manon Vounckx, Jolien I. Kessels, Justine Lauwyck, Gil Awada, Anne-Marie Vanbinst, Bart Neyns

{"title":"Detection of cell-free tumor DNA in cerebrospinal fluid as a diagnostic biomarker for leptomeningeal melanoma metastasis: A case series","authors":"Iris Dirven, Manon Vounckx, Jolien I. Kessels, Justine Lauwyck, Gil Awada, Anne-Marie Vanbinst, Bart Neyns","doi":"10.1111/pcmr.13186","DOIUrl":"10.1111/pcmr.13186","url":null,"abstract":"Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment. In this single-center case series, detection of BRAFV600- and NRASQ61-mutant cell-free tumor DNA (cfDNA) in CSF was evaluated as a complementary diagnostic biomarker. In 12 patients with clinical suspicion of LMM, a retrospective analysis of MRI, CSF cytology and cfDNA analysis on 1 mL of CSF using the Idylla® platform was carried out. Nine patients displayed MRI abnormalities suggesting LMM. CSF analysis identified malignant cells in three patients (including one without MRI abnormalities). BRAFV600- or NRASQ61-mutant cfDNA was detected in CSF of nine patients (eight with and one without MRI abnormalities; all patients with positive CSF cytology). Subsequent follow-up confirmed LMM in all patients with positive and in one patient with a negative CSF cfDNA analysis (sensitivity 81.8%; specificity 100%). Our findings suggest that analyzing BRAFV600- and NRASQ61-mutant cfDNA in CSF using the Idylla® platform holds promise as a sensitive and specific complementary diagnostic biomarker for LMM, particularly in case of inconsistency between imaging and CSF cytology. The 110-min analysis can facilitate urgent treatment decisions.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"822-830"},"PeriodicalIF":3.9,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genome wide association study and meta-analysis identified multiple new risk loci for freckles in 4813 Chinese individuals 全基因组关联研究和荟萃分析在 4813 名中国人中发现了多个新的雀斑风险位点。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-06 DOI: 10.1111/pcmr.13183

Sihan Luo, Zhuo Li, Minhao Wang, Zhili Liu, Daiyue Wang, Yuanming Bai, Huiyao Ge, Yafen Yu, Yanxia Yu, Weiwei Chen, Yirui Wang, Chang Zhang, Jing Yu, Can Song, Chengzhi Lv, Qi Zhen, Yang Han, Liangdan Sun

引用次数: 0

Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab 用达拉菲尼、曲美替尼和尼韦单抗治疗一名脑外膜黑色素瘤患者后获得持久完全应答。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-07-03 DOI: 10.1111/pcmr.13179

Sarah E. Lochrin, Darren J. Buonocore, Robert J. Young, Thomas J. Kaley, Michael A. Postow, Jedd D. Wolchok, Alexander N. Shoushtari, Parisa Momtaz, Allison S. Betof Warner, Margaret K. Callahan

{"title":"Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab","authors":"Sarah E. Lochrin, Darren J. Buonocore, Robert J. Young, Thomas J. Kaley, Michael A. Postow, Jedd D. Wolchok, Alexander N. Shoushtari, Parisa Momtaz, Allison S. Betof Warner, Margaret K. Callahan","doi":"10.1111/pcmr.13179","DOIUrl":"10.1111/pcmr.13179","url":null,"abstract":"Leptomeningeal disease (LMD) is a devastating complication of melanoma with a dismal prognosis. We present the case of a young man with stage IV BRAF V600E mutant melanoma with lung, lymph node, and brain metastases initially treated with ipilimumab and nivolumab, who subsequently developed LMD. Upon change to BRAF/MEK targeted therapy with nivolumab, a durable complete response was achieved and remains ongoing, off treatment, 7 years from diagnosis. Management of symptomatic LMD remains a critical unmet clinical challenge, with limited clinical trial data. This exceptional case is instructive, as the first published case of the use of the triplet, and the first durable response with therapy discontinuation, in melanoma LMD. The triple-drug regimen may be considered a viable option in fit patients. This case highlights the potential for long-term disease control and the critical and urgent need to develop clinical trials inclusive of patients with LMD to define the best treatment strategies.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"801-807"},"PeriodicalIF":3.9,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141496499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ToF-SIMS imaging reveals changes in tumor cell lipids during metastatic progression of melanoma ToF-SIMS 成像揭示了黑色素瘤转移过程中肿瘤细胞脂质的变化。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-06-29 DOI: 10.1111/pcmr.13182

Noora Neittaanmäki, Oscar Zaar, Kevin Sjögren Cehajic, Kelly Dimovska Nilsson, Dimitrios Katsarelias, Roger Olofsson Bagge, John Paoli, John S. Fletcher

{"title":"ToF-SIMS imaging reveals changes in tumor cell lipids during metastatic progression of melanoma","authors":"Noora Neittaanmäki, Oscar Zaar, Kevin Sjögren Cehajic, Kelly Dimovska Nilsson, Dimitrios Katsarelias, Roger Olofsson Bagge, John Paoli, John S. Fletcher","doi":"10.1111/pcmr.13182","DOIUrl":"10.1111/pcmr.13182","url":null,"abstract":"Most melanomas progress from radial to vertical growth phase before spreading locoregionally and distally. Much is still unknown about the metabolic changes in the tumor cells and their microenvironment during this metastatic progression. We aimed to gain new insight into the molecular characteristics of melanoma in regard to spatial lipidomics to deliver new knowledge regarding tumor metastatic progression. We included 10 fresh tumor samples from 10 patients including two in situ melanomas, two invasive primary melanomas, and six metastatic melanomas (four in-transit metastases and two distant metastases). In addition, we analyzed four healthy skin controls from the same patients. Time-of-flight imaging secondary ion mass spectrometry (ToF-SIMS) enabled detailed spatial-lipidomics that could be directly correlated with conventional histopathological analysis of consecutive H&E-stained tissue sections. Significant differences in the lipid profiles were found in primary compared to metastatic melanomas, notably an increase in phosphatidylethanolamine lipids relative to phosphatidylinositol lipids and an increase in GM3 gangliosides in the metastatic samples. Furthermore, analysis of the data from in transit versus distant metastases samples highlighted that specific phospholipids, and a difference in the long versus shorter chain GM3 gangliosides, discriminated the metastatic routes. Further studies are warranted to verify these preliminary findings. Lipidomic changes could serve as a novel biomarker for tumor progression and even serve as a target for novel treatments. Furthermore, analyzing the lipid profiles could help to differentiate between primary and metastatic melanomas in challenging cases.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"793-800"},"PeriodicalIF":3.9,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141464671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Age and urban–rural disparities in cutaneous melanoma mortality rates in the United States during the COVID-19 pandemic COVID-19 大流行期间美国皮肤黑色素瘤死亡率的年龄和城乡差异。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-06-13 DOI: 10.1111/pcmr.13181

Ting Hu, Zhimiao Ma, Yuxin Guo, Sikai Qiu, Fan Lv, Ying Liu, Wee Han Ng, Jian Zu, Yee Hui Yeo, Fanpu Ji, Ernest Y. Lee, Zhengxiao Li

{"title":"Age and urban–rural disparities in cutaneous melanoma mortality rates in the United States during the COVID-19 pandemic","authors":"Ting Hu, Zhimiao Ma, Yuxin Guo, Sikai Qiu, Fan Lv, Ying Liu, Wee Han Ng, Jian Zu, Yee Hui Yeo, Fanpu Ji, Ernest Y. Lee, Zhengxiao Li","doi":"10.1111/pcmr.13181","DOIUrl":"10.1111/pcmr.13181","url":null,"abstract":"Most recent studies on the coronavirus disease 2019 (COVID-19) pandemic and cutaneous melanoma (CM) focused more on delayed diagnosis or advanced presentation. We aimed to ascertain mortality trends of CM between 2012 and 2022, focusing on the effects of the COVID-19 pandemic. In this serial population-based study, the National Vital Statistics System dataset was queried for mortality data. Excess CM-related mortality rates were estimated by calculating the difference between observed and projected mortality rates during the pandemic. Totally there were 108,853 CM-associated deaths in 2012–2022. CM-associated mortality saw a declining trend from 2012 to 2019 overall. However, it increased sharply in 2020 (ASMR 3.73 per 100,000 persons, 5.95% excess mortality), and remained high in 2021 and 2022, with the ASMRs of 3.82 and 3.81, corresponding to 11.17% and 13.20% excess mortality, respectively. The nonmetro areas had the most pronounced rise in mortality with 12.20% excess death in 2020, 15.33% in 2021 and 20.52% in 2022, corresponding to a 4–6 times excess mortality risk compared to large metro areas during the pandemic. The elderly had the most pronounced rise in mortality, but the mortality in the younger population was reduced.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 6","pages":"783-792"},"PeriodicalIF":3.9,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141309806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journey through the spectacular landscape of melanocortin 1 receptor 穿越黑色素皮质素 1 受体的壮丽景观。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-06-10 DOI: 10.1111/pcmr.13180

P. R. Upadhyay, V. B. Swope, R. J. Starner, L. Koikov, Z. A. Abdel-Malek

{"title":"Journey through the spectacular landscape of melanocortin 1 receptor","authors":"P. R. Upadhyay, V. B. Swope, R. J. Starner, L. Koikov, Z. A. Abdel-Malek","doi":"10.1111/pcmr.13180","DOIUrl":"10.1111/pcmr.13180","url":null,"abstract":"The physiological role of α-melanocyte stimulating hormone in regulating integumental pigmentation of many vertebrate species has been recognized since the 1960's. However, its physiological significance for human pigmentation remained enigmatic until the 1990's. α-Melanocyte stimulating hormone and related melanocortins are synthesized locally in the skin, primarily by keratinocytes, in addition to the pituitary gland, and therefore act as paracrine factors for melanocytes. Human melanocytes express the melanocortin 1 receptor, which recognizes α-melanocyte stimulating hormone and the related adrenocorticotropic hormone as agonists. This review summarizes the current knowledge of the pleotropic effects of the activated melanocortin 1 receptor that maintain human melanocyte homeostasis by regulating melanogenesis and the response to environmental stressors, mainly solar radiation. Certain allelic variants of the melanocortin 1 receptor gene are associated with specific pigmentary phenotypes in various human populations. Variants associated with red hair phenotype compromise the function of the encoded receptor. Activation of the human melanocortin 1 receptor regulates eumelanin synthesis and enhances DNA damage response of melanocytes to solar radiation and oxidative stressors. We describe how synthetic selective melanocortin 1 receptor agonists can be efficacious as sunless tanning agents, for treatment of vitiligo and photosensitivity disorders, and for prevention of skin cancer, including melanoma.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"37 5","pages":"667-680"},"PeriodicalIF":3.9,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.13180","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xenopus as a model system for studying pigmentation and pigmentary disorders 将爪蟾作为研究色素沉着和色素失调的模型系统。

IF 3.9 3区医学

Pigment Cell & Melanoma Research Pub Date : 2024-06-07 DOI: 10.1111/pcmr.13178

Joudi El Mir, Ali Nasrallah, Nadine Thézé, Muriel Cario, Hussein Fayyad-Kazan, Pierre Thiébaud, Hamid-Reza Rezvani

{"title":"Xenopus as a model system for studying pigmentation and pigmentary disorders","authors":"Joudi El Mir, Ali Nasrallah, Nadine Thézé, Muriel Cario, Hussein Fayyad-Kazan, Pierre Thiébaud, Hamid-Reza Rezvani","doi":"10.1111/pcmr.13178","DOIUrl":"10.1111/pcmr.13178","url":null,"abstract":"Human pigmentary disorders encompass a broad spectrum of phenotypic changes arising from disruptions in various stages of melanocyte formation, the melanogenesis process, or the transfer of pigment from melanocytes to keratinocytes. A large number of pigmentation genes associated with pigmentary disorders have been identified, many of them awaiting in vivo confirmation. A more comprehensive understanding of the molecular basis of pigmentary disorders requires a vertebrate animal model where changes in pigmentation are easily observable in vivo and can be combined to genomic modifications and gain/loss-of-function tools. Here we present the amphibian Xenopus with its unique features that fulfill these requirements. Changes in pigmentation are particularly easy to score in Xenopus embryos, allowing whole-organism based phenotypic screening. The development and behavior of Xenopus melanocytes closely mimic those observed in mammals. Interestingly, both Xenopus and mammalian skins exhibit comparable reactions to ultraviolet radiation. This review highlights how Xenopus constitutes an alternative and complementary model to the more commonly used mouse and zebrafish, contributing to the advancement of knowledge in melanocyte cell biology and related diseases.","PeriodicalId":219,"journal":{"name":"Pigment Cell & Melanoma Research","volume":"38 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0